Medicare premiums to jump 10% heading into 2026
Most Medicare enrollees will face premiums that are 10% higher next year, creating budget anxiety for millions of seniors.
STAT+: Pfizer closes $10 billion Metsera deal
And more biotech news brought to you by The Readout newsletter
Judge says he’ll approve opioid settlement with OxyContin maker Purdue and Sackler family
A federal bankruptcy court judge on Friday said he will approve OxyContin-maker Purdue Pharma’s latest deal to settle thousands of lawsuits over the toll of opioids.
Opinion: Celebrating a new, faster path to gene-editing medicines on demand
The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it would mean for families.
Advocates decry intersex exceptions in trans health bans
Restrictions on gender-affirming care for minors consistently allow exceptions for minors with intersex traits, a new study finds.
Merck’s heart disease win and the FDA’s new drug regulator
This week on "The Readout LOUD" podcast: What does Rick Pazdur's new role mean for the FDA? And how much credit can the president take for lowering GLP-1 drug prices?
STAT+: Kura Oncology secures approval for leukemia drug, its first
The FDA approved a drug made by Kura Oncology to treat patients with a certain type of genetically altered leukemia.
STAT+: GOP ACA proposal complicates negotiations
In today's D.C. Diagnosis newsletter, the GOP's Affordable Care Act proposal gets a cold reception from think tanks, plus more of the latest Washington news.
STAT+: Makary, Prasad outline pathway for bespoke gene therapy
And other biotech news, brought to you by The Readout
STAT+: Pfizer signals brewing digital health work
In this edition of STAT's Health Tech newsletter: Pfizer hints at its brewing digital health work, and more health tech news.